Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents
- PMID: 34270752
- PMCID: PMC8344506
- DOI: 10.1093/jpids/piab061
Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents
References
-
- Johns Hopkins University & Medicine Coronavirus Resource Center. COVID-19 Global Cases Data Center 2020. https://coronavirus.jhu.edu/data/. Accessed 16 June 2021.
-
- Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic [press release]. US Food and Drug Administration, May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Accessed 16 June 2021.
-
- Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics 2021. - PubMed
-
- Advisory Committee on Immunization Practices. COVID-19 VaST Work Group Report – May 17, 2021. https://www.cdc.gov/vaccines/acip/work-groups-vast/report-2021-05-17.html. Accessed 16 June 2021.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
